E-Mail
IMAGE: Patients participating in a group medical visit, shown to help reduce blood pressure among patients with hypertension or diabetes when combined with a microfinance intervention view more
Credit: AMPATH Kenya
While cardiovascular disease (CVD) remains the leading cause of death globally, new research led by NYU Grossman School of Medicine and Moi University School of Medicine (Kenya) found that addressing and incorporating social determinants of health (such as poverty and social isolation) in the clinical management of blood pressure in Kenya can improve outcomes for patients with diabetes or hypertension.
The study recently published online in The
email article
Primary percutaneous coronary intervention (PCI) was feasible for treating COVID-19 patients with ST-segment elevation MI (STEMI), though prognosis is variable, according to a study from the NACMI registry.
COVID-positive STEMI patients had a 36% risk of the primary outcome of a composite of in-hospital death, stroke, recurrent MI, or repeat unplanned revascularization. This was significantly higher than both the 13% risk observed in patients suspected of infection without testing positive, and the 5% risk among matched controls (
P 0.001 for both), reported a group led by Santiago Garcia, MD, of the Minneapolis Heart Institute Foundation in Minnesota.
The elevated risk was driven primarily by differences in in-hospital mortality (33% vs 11% vs 4%, respectively) and stroke (3% vs 2% vs 0%), they noted in the
Email
New research led by NYU Grossman School of Medicine and Moi University School of Medicine in Kenya found that addressing and incorporating social determinants of health such as poverty and social isolation in the clinical management of blood pressure in Kenya can improve outcomes for patients who have diabetes or hypertension.
Journal of the American College of Cardiology, found that after one year, patients who received a multi-component intervention that combined community microfinance groups with group medical visits where patients with similar medical conditions met together with a clinician and community health worker had a 44 percent greater reduction in systolic blood pressure (SBP) compared with patients who received standard care for hypertension or diabetes.
Le piment pour vivre plus longtemps ? maxisciences.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from maxisciences.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy
Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the
Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17, 2021, 3:50 PM CEST (Central European Summer Time) by Andrew Buckler, Founder and CTO of Elucid. As previously reported and published in the